News und Analysen
Veeva to Present at the Barclays 2019 Global Technology, Media & Telecommunications Conference
Veeva Systems (NYSE:VEEV) today announced that Tim Cabral, CFO, will present at the Barclays 2019 Global Technology, Media & Telecommunications Conference on Thursday, December 12, 2019, at 9:00
New Veeva OpenData Explorer Provides Online Access to Real-time HCP, HCO, Affiliation, and Compliance Data
Life sciences companies want the freedom to use their customer reference data in the way that best meets their business needs. To give the industry even greater flexibility and choice in how they
New Innovations Give Business Users Enhanced Flexibility in Veeva CRM
Veeva Systems (NYSE:VEEV) today announced new capabilities that give business users greater flexibility in Veeva CRM for improved collaboration and productivity. Salesforce Lightning Business Apps
NanoString Announces Exclusive License of nCounter Diagnostic Assets and Rights to Veracyte
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced a strategic transaction to exclusively license select
Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the appointment of Dr. An van Es-Johansson, M.D. to its Board of Directors, effective immediately. Dr. van Es-Johansson
Evotec: Einstieg bei Celmatix, aber...
In einem insgesamt doch eher schwachen Marktumfeld sticht die Aktie des Hamburger Biotechkonzerns Evotec (WKN: 566480) heute positiv heraus. Grund hierfür dürfte eine Ad hoc-Mitteilung von heute
Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and
Nature Medicine Publication Highlights Use of NanoString’s Hyb & Seq Technology to Perform Rapid Genotypic and Phenotypic Antibiotic Susceptibility Testing
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products, today announced the publication of a
Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing approval of NERLYNX®
1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on
Navidea Biopharmaceuticals Wins Summary Judgment in Ohio
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Biofrontera: Aktie nach Insider-Trades mit Auftrieb
Vorstände zählen wieder zu den Käufern in der Biofrontera-Aktie (WKN: 604611).
CEO Prof. Dr. Hermann Lübbert kaufte heute für knapp 50.000 Euro zu einem durchschnittlichen Kurs von 4,92 Euro. Zu
CORRECTING and REPLACING Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries
Novocure and the AACR Announce 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce today their 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research program. The program
Morphosys: Noch Schnäppchenpreise?
Aktuell steuert die Morphosys-Aktie (WKN: 663200) auf ein neues Jahreshoch zu. Dieses liegt bei 113,80 Euro und datiert vom August. Sind das aktuell also Schnäppchenpreise?
Q3-Bericht mit Licht und
Epigenomics: Steht der Durchbruch endlich bevor?
Exakt +99% waren im November für flinke Anleger in Epigenomics-Aktien (WKN: A11QW5) von 0,83 auf 1,65 Euro am Freitag drin. Wie es weitergeht, erfährst du nur einen Klick weiter.
Das
Sensorion Announces Results From SENS-111 Phase 2b Trial in Acute Unilateral Vestibulopathy
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN / PEA-PME eligible), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore
Novus Therapeutics to Participate in Two Investor Conferences
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the
EOS imaging RECEIVES U.S. FDA 510(K) CLEARANCE FOR EOSedge™ ITS NEW GENERATION INNOVATIVE IMAGING SYSTEM
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191128005574/en/
EOSedge™ (Photo: Business Wire)
EOS imaging
Antibe Therapeutics Provides Corporate Update and Reports Q2 2020 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate
ChemoCentryx: Nach +300% - wie geht es jetzt weiter?
Kürzlich explodierte die Aktie des US-amerikanischen Biotechunternehmens ChemoCentryx (WKN: A0NBM2) bekanntlich an einem einzigen Handelstag um mehr als +300% (wir berichteten). Grund hierfür waren
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that on November 26, 2019, the independent members of the Company's Board of Directors granted Badrul Chowdhury, M.D
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical
IMV to Participate at Two Upcoming Investor Conferences
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that the IMV’s executive
ICON plc to Present at Evercore ISI 2nd Annual HealthCONx Conference
ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr